access to vaccine become with more variance emerging? access to vaccine become with more variance emerging? we certainly need to net variance emerging? we certainly need to get vaccines variance emerging? we certainly need to get vaccines to variance emerging? we certainly need to get vaccines to the variance emerging? we certainly need to get vaccines to the people - variance emerging? we certainly need to get vaccines to the people who - to get vaccines to the people who need them, that s clear. in the kovacs facility as you know has been established to do that. what s important now is that all countries work together including those countries that need to vaccine. in those countries need to put it as a priority and make sure that somehow they get the vaccine, the facility is there, who is they are, they need to be requesting vaccines. and then they need to deliver them to the people who need them. and it s very difficult in some countries where they have never been adult vacc
is? well, that evening. actually, what happened is? well, that evening. actually, what happened when is? well, that evening. actually, what happened when the - is? well, that evening. actually, what happened when the vaccine is? well, that evening. actually, - what happened when the vaccine came to the markets, the country back up so many bioassays that it left a note covax a little short of bioassays, and as you are saying previously, like when india had its devastating resurgence, basically, the indian supplier, which where the main supplierfor the the indian supplier, which where the main supplier for the kovacs facility really divert the doses domestically, so from currently the promise of 120 million, of those that arrive, we only delivered 67 doses, really, 67 million doses, currently. of course, we are happy about countries sharing their dialysis and we welcome now the united states announcing today about donating half a million doses.